Navigation Links
Switching to new anti-bacterial targets: Riboswitches

The recently emerged field of bacterial riboswitches may be a good hunting ground for effective targets against bacterial infection, according to a report by Yale researchers in the journal Chemistry and Biology.

Riboswitches are RNA elements that control gene expression in essential metabolic pathways. Researchers in the laboratory of Ronald R. Breaker, the Henry Ford II Professor of Molecular, Cellular and Developmental Biology at Yale, showed that a riboswitch controlling vitamin B1 (thiamine) levels is disrupted in the presence of pyrithiamine, a toxic compound related to the vitamin.

Bacteria and fungi fail to grow in pyrithiamine and become resistant by acquiring mutations in their riboswitches. This work, in combination with the recently solved crystal structures of purine riboswitches, opens a path to the directed design of drugs targeting riboswitches for use as antibiotics.

According to the researchers, it is inevitable that bacteria will evolve and that the drugs we use to cure bacterial infections will eventually become ineffective. While it is often possible to alter existing drugs slightly, they suggest that a longer term and more attractive solution is to create entirely new drugs that target bacteria in completely new ways. This approach lengthens the useful clinical lifetime of a drug and makes it possible to tackle resistant 'superbugs' with combinations of drugs.

The analog, pyrithiamine, was synthesized decades ago to study the then new field of vitamin nutrition. It was quickly found to be toxic but the mechanism was incompletely understood. Breaker and coworkers show that pyrithiamine is metabolized and binds to the riboswitch controlling thiamine.

Co-authors at Yale on the work are Narasimhan Sudarsan, Smadar Cohen-Chalamish, Shingo Nakamura and Gail Mitchel l Emilsson. The study was funded by the Defense Advanced Research Projects Agency, National Institutes of Health, and the David and Lucile Packard Foundation.

Breaker, a Howard Hughes Medical Institute Investigator, is co founder of BioRelix, a company pursuing licensing of intellectual property related to riboswitches.


'"/>

Source:Yale University


Related biology news :

1. Switching genes to overdrive improves muscular dystrophy symptoms in mice
2. Mayo Clinic collaboration mining of ancient herbal text leads to potential new anti-bacterial drug
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/18/2017)... 2017 MedNet Solutions , an ... entire spectrum of clinical research, is proud to ... for the organization in terms of corporate growth, ... products and services. The company,s exceptional achievements can ... iMedNet ™ – ...
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... of the future.  1,000 participants were simply asked which office ... which we may consider standard issue.  Insights on what ... were also gathered from futurists and industry leaders including ... James Canton .  Some of these ...
(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... Calif. , Jan. 19, 2017  ArmaGen, ... Mathias Schmidt , Ph.D., as chief executive officer, ... of directors. Dr. Schmidt brings to ArmaGen more than ... the research and development of biotherapeutics and pharmaceuticals. ... executive with the diverse experience and skillset necessary ...
(Date:1/19/2017)... ... January 18, 2017 , ... LabRoots , ... from around the world, was today awarded the "Best Science & Technology Social ... on merit and decided upon by a dedicated team of researchers and analysts. ...
(Date:1/19/2017)... , Jan. 18, 2017 The ... reach USD 92.9 billion by 2025, according to ... Pharmaceutical industry has been adaptive of the function ... early as 2002. Among the services outsourced, clinical ... For instance, Johnson & Johnson was the first ...
(Date:1/19/2017)... FRANKLIN LAKES, N.J. , Jan. 18, 2017 BD ... medical technology company, announced today that it will host a live ... 2017, at 1 p.m. (ET). The webcast can ... will be available for replay through Tuesday, January 31, 2017. ... About BD ...
Breaking Biology Technology: